Results 11 to 20 of about 1,130 (117)

Preoperative Avapritinib for Localized PDGFRA‐Mutant GIST: Marked Pathologic Response, but Limited Feasibility at Standard Dosing

Cancer Medicine
Background Avapritinib is a selective tyrosine kinase inhibitor approved for advanced PDGFRA exon 18–mutant gastrointestinal stromal tumors (GIST), including the imatinib‐resistant D842V variant.
Tannaz Ranjbarian, Mark Antkowiak, Shirley Sarno, Shumei Kato, Adam M. Burgoyne, Skye C. Mayo, Michael C. Heinrich, Paul T. Fanta, Jason K. Sicklick   +8 more
doaj   +2 more sources

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study [PDF]

Blood Advances
: Advanced systemic mastocytosis (AdvSM), a clonal hematologic neoplasm driven predominantly by D816V-mutant KIT, is often characterized by organ damage. Associated hematologic neoplasms (AHNs; usually myeloid) are often present, leading to poor survival.
Jason Gotlib, Andreas Reiter, Deepti H. Radia, Iván Álvarez-Twose, Michael W. Deininger, Tracy I. George, Jens Panse, Andrzej Mital, Kristen M. Pettit, Alessandro M. Vannucchi, Uwe Platzbecker, Olivier Hermine, Amro Elshoury, Cristina Bulai Livideanu, Ruben Mesa, Celalettin Ustun, Massimo Triggiani, Ingunn Dybedal, Joseph G. Jurcic, Roberta Zanotti, Stephen T. Oh, Abdulraheem Yacoub, Elizabeth O. Hexner, Prithviraj Bose, Stephanie G. Lee, Wolfgang R. Sperr, Elizabeth A. Griffiths, Matthew Butler, Johannes Lübke, Ilda Bidollari, Hui-Min Lin, Svetlana Rylova, Saša Dimitrijević, Javier I. Muñoz-González, Daniel J. DeAngelo   +34 more
doaj   +2 more sources

Case report: A case of mast cell leukemia treated with avapritinib: from diagnostic challenge to transplantation [PDF]

Frontiers in Oncology
Systemic mastocytosis (SM) is a rare hematological neoplasm characterized by the proliferation and accumulation of clonal mast cells (MCs) in the skin, bone marrow, and other extracutaneous organs.
Danilo Giuseppe Faraci, Danilo Giuseppe Faraci, Daniela Caravelli, Daniela Caravelli, Fabrizio Carnevale Schianca, Fabrizio Carnevale Schianca, Elena Zaniol, Fiorenza Enrico, Carlo Boffano, Carmelo Labate, Greta Sterpi, Greta Sterpi, Alessandro Fornari, Alessandro Fornari, Valentina Sangiorgio, Valentina Sangiorgio, Elena Crisà   +16 more
doaj   +2 more sources

Avapritinib reduces symptoms and mast cell burden in systemic mastocytosis [PDF]

Allergy, Asthma & Clinical Immunology
Background Mastocytosis is driven by a clonal expansion of mast cells, commonly triggered by the KIT D816V mutation which is present in over 90% of adult patients.
Paula Nöldeke, Oliver Schmalz, Hans Kvasnicka, Jens Panse, Silke C. Hofmann   +4 more
doaj   +2 more sources

Skeletal Involvement in Systemic Mastocytosis: Pathophysiology, Clinical Management, Standards of Care, and Novel Therapeutic Strategies [PDF]

Cells
Systemic mastocytosis comprises a group of clonal mast cell disorders characterized by multisystem involvement. Bone involvement represents a major source of morbidity, particularly in young men affected by indolent systemic mastocytosis.
Manlio Fazio, Adele Bottaro, Maria Elisa Nasso, Fabio Stagno, Alessandro Allegra   +4 more
doaj   +2 more sources

Negative outcomes associated with tyrosine kinase inhibitors during management of gastrointestinal stromal tumors: examination of data from the FDA adverse event reporting system [PDF]

Frontiers in Oncology
BackgroundSince the approval of Tyrosine kinase inhibitors (TKIs) in gastrointestinal stromal tumors (GISTs), the survival of patients with metastatic GISTs have been remarkably improved. But clinically, the adverse effects (AEs) are the major barrier to
Yuxuan Ma, Yuxuan Ma, Ahui Fan, Yuhao Wang, Yuhao Wang, Shenhui Xu, Xin Liu, Xin Liu, Jianjun Yang   +8 more
doaj   +2 more sources

A case of indolent systemic mastocytosis responding to treatment with Avapritinib

Clinical Case Reports (discontinued)
Key Clinical Message Low dose Avapritinib is a new medication that is a potential treatment option not just for advanced systemic mastocytosis, but also for the indolent form.

exaly   +2 more sources

Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications [PDF]

Journal of Experimental & Clinical Cancer Research
Background Lenvatinib, a tyrosine kinase receptor inhibitor, has emerged as a frontline therapeutic strategy for the management of advanced hepatocellular carcinoma (HCC). However, the modest response rate observed with lenvatinib and the rapid emergence
Bixing Zhao, Yang Zhou, Niangmei Cheng, Xiaoyuan Zheng, Geng Chen, Xin Qi, Xiangzhi Zhang, Fei Wang, Qiuyu Zhuang, Yehuda G. Assaraf, Xiaolong Liu, Yingchao Wang, Yongyi Zeng   +12 more
doaj   +2 more sources

Refractory cutaneous symptoms in systemic mastocytosis [PDF]

JAAD Case Reports
Laura Gleason, MD, Safiyyah A. Bhatti, MD, Molly Wallace, BS, Jason B. Lee, MD, Onder Alpdogan, MD, Neda Nikbakht, MD, PhD   +5 more
doaj   +2 more sources

Photosensitivity From Avapritinib: Pharamacovigilance Analysis

JMIR Dermatology, 2022
Certain protein kinase inhibitors have been reported to cause photosensitivity. Avapritinib is a tyrosine kinase inhibitor that was approved in January 2020.
Ajit Venkatakrishnan, Brandon Chu, Pushkar Aggarwal   +2 more
doaj   +1 more source